Halozyme Therapeutics HALO Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's prepaid & other current?
- Halozyme Therapeutics (HALO) reported prepaid & other current of $70.96M in Q1 2026.
- How has Halozyme Therapeutics's prepaid & other current changed year-over-year?
- Halozyme Therapeutics's prepaid & other current increased by 59.0% year-over-year, from $44.62M to $70.96M.
- What is the long-term trend for Halozyme Therapeutics's prepaid & other current?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's prepaid & other current has grown at a 18.0% compound annual growth rate (CAGR), from $28.27M to $64.64M.
- What does prepaid & other current mean?
- Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.